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Background: Diabetes mellitus is associated with an increased risk of dementia. We aimed to comprehensively analyze the inci-
dence and risk factors for dementia and young-onset dementia (YOD) in diabetic patients in Korea using the National Health In-
surance Service data. 
Methods: Between January 1, 2009 and December 31, 2012, a total of 1,917,702 participants with diabetes were included and fol-
lowed until the date of dementia diagnosis or until December 31, 2015. We evaluated the incidence and risk factors for all demen-
tia, Alzheimer’s disease (AD), and vascular dementia (VaD) by Cox proportional hazards analyses. We also compared the impact 
of risk factors on the occurrence of YOD and late-onset dementia (LOD). 
Results: During an average of 5.1 years of follow-up, the incidence of all types of dementia, AD, or VaD was 9.5, 6.8, and 1.3/1,000 
person-years, respectively, in participants with diabetes. YOD comprised 4.8% of all dementia occurrence, and the ratio of AD/
VaD was 2.1 for YOD compared with 5.5 for LOD. Current smokers and subjects with lower income, plasma glucose levels, body 
mass index (BMI), and subjects with hypertension, dyslipidemia, vascular complications, depression, and insulin treatment de-
veloped dementia more frequently. Vascular risk factors such as smoking, hypertension, and previous cardiovascular diseases 
were more strongly associated with the development of VaD than AD. Low BMI and a history of stroke or depression had a stron-
ger influence on the development of YOD than LOD. 
Conclusion: The optimal management of modifiable risk factors may be important for preventing dementia in subjects with dia-
betes mellitus.
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INTRODUCTION
Dementia is a global epidemic; the number of people with de-
mentia worldwide was estimated at 47.47 million in 2015 and 
expected to reach 135.46 million in 2050 [1]. In several studies 
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of dementia by approximately 50% [2]. This increased risk in 
subjects with type 2 diabetes mellitus translates into an average 
earlier onset of dementia of 2.5 years compared with subjects 
without diabetes [3].
Whether diabetes is an actual risk factor for Alzheimer’s dis-
ease (AD) has been the focus of many studies [4]; however, the 
risk factors for dementia in patients with diabetes have been 
evaluated in relatively few studies [5,6]. Results from previous 
studies showed that diabetic participants with poor glycemic 
control [7], long duration of diabetes [5], pre-existing micro- 
or macrovascular complications [5,8], and severe hypoglyce-
mia [8] were at increased risk of dementia. However, in those 
studies, the number of study participants was small [5,7], the 
assessment of confounding factors was limited [6,8], and no 
differentiation between specific types of dementia was present-
ed [5,6,8]. In only one study in Taiwan, the relationship be-
tween diabetes and subsequent AD incidence was investigated 
using nationwide population data [6]. However, the authors 
did not have access to data such as metabolic risk factors, 
smoking, alcohol, and socioeconomic class, because the Na-
tional Health Insurance Claim data were based only on the di-
agnosis codes. 
Recently, concerns have increased regarding young-onset 
dementia (YOD), in which symptoms occur before the age of 
65 years. YOD has been estimated to comprise approximately 
8% of new dementia cases in Australia [9]. Although AD is the 
most common type of YOD, secondary dementia is more fre-
quent in YOD patients compared with late-onset dementia 
(LOD) [10,11]. Due to its rarity, the diagnosis of YOD is often 
delayed, but has a significant psychosocial effect because the 
most productive years of patients’ lives are affected [10].
In the present study, the National Health Insurance Service 
(NHIS) data were used to estimate the effect of diabetes on the 
development of dementia in general, and specifically on AD or 
vascular dementia (VaD). Furthermore, the possible risk fac-
tors for dementia in diabetes were comprehensively investigat-
ed. Lastly, the incidence rate and specific risk factors for YOD 
in diabetes were examined. 
METHODS
Design, study setting, and participants
The NHIS is a government-operated mandatory social health 
insurance program that covers almost the entire Korean popu-
lation (approximately 97%). The NHIS in Korea comprises 
comprehensive sets of health information for approximately 50 
million Koreans [12,13]. The NHIS, which contains claims and 
mortality data can be accessed by all researchers whose proto-
cols are approved by both a NHIS Review Committee and an 
Institutional Review Board (IRB). This study protocol was ap-
proved by the IRB of Korea University Ansan Hospital (IRB 
number: 2019AS0138). Informed consent was waived by the 
board. 
From this database, 2,482,918 individuals 40 years of age or 
older with diabetes who underwent health checkups provided 
by the NHIS between January 1, 2009 and December 31, 2012 
were selected. Then, patients diagnosed with dementia prior to 
enrollment (n=20,652), and those with any missing data (n= 
544,564) were excluded. A total of 1,917,702 participants were 
finally included as the study population and followed up until 
dementia was diagnosed or until December 31, 2015 (Supple-
mentary Fig. 1). 
Demographic factors
Body mass index (BMI) was calculated by dividing the weight 
(kg) by height squared (m2). Based on BMI, participants were 
classified as underweight (<18.5), normal weight (18.5 to 22.9), 
overweight (23 to 24.9), obese (25 to 29.9), or severely obese 
(≥30) [14]. Blood samples were taken after an overnight fast 
and quality control procedures followed the Korean Associa-
tion of Laboratory Quality Control guidelines. 
Detailed information regarding smoking status, alcohol con-
sumption, physical activity, and past medical history of study 
participants was assessed via standardized self-reported ques-
tionnaires. Subjects were categorized as non-smokers, ex-
smokers, or current smokers. Heavy drinkers were defined as 
individuals who consumed ≥30 g of alcohol per day [15]. 
Physical activity was divided into exercising less strenuously 
versus more than three times a week for at least 20 minutes per 
day. The baseline comorbidities of participants were identified 
based on the combination of past medical history and clinical 
and pharmacy International Classification of Diseases (ICD-
10) codes. 
Definitions
Individuals with diabetes were defined as either patients who 
were both prescribed anti-diabetic drugs and had the presence 
of ICD-10 codes (E11–E14), or patients with fasting glucose 
levels >126 mg/dL derived from the health check-up database 
[16]. Treatment of diabetes was defined as NHIS medication 
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data for drugs prescribed during the same year as the health 
examination. Anti-diabetic medications were categorized as 
oral hypoglycemic agents (OHAs) and insulin. The OHAs dis-
pensed in the pharmacy during the study period consisted of 
six classes (sulfonylurea, biguanide, alpha-glucosidase inhibi-
tor, thiazolidinedione, dipeptidyl peptidase 4 inhibitor, and 
meglitinide). Duration of diabetes was calculated from the first 
diagnosis of diabetes to the baseline examination on study en-
try. The diagnosis of diabetic retinopathy was defined based on 
the ICD-10 code H36.0. 
The presence of hypertension was defined as a systolic/dia-
stolic blood pressure ≥140/90 mm Hg or the presence of at least 
one claim per year for the prescription of antihypertensive 
agents under ICD-10 codes (I10–I13, I15). The presence of dys-
lipidemia was defined as total cholesterol ≥6.21 mmol/L or the 
presence of at least one claim per year for the prescription of an-
tihyperlipidemic agents under ICD-10 codes (E78). Estimated 
glomerular filtration rate (eGFR) was calculated using the equa-
tion from the Modification of Diet in Renal Disease (MDRD) 
study: eGFR=175×serum creatinine–1.154×age–0.203×0.742 (for 
women). The eGFR <60 mL/min/1.73 m2 was defined as chron-
ic kidney disease (CKD) [17]. The history of cardiovascular dis-
eases (CVDs), stroke, myocardial infarction, and angina pecto-
ris, was evaluated using standardized questionnaires. Myocardi-
al infarction and angina pectoris were regarded as ischemic 
heart diseases (IHDs). Depression was defined using ICD-10 
codes (F32–34). 
Dementia was determined based on prescribed anti-demen-
tia medications (rivastigmine, galantamine, memantine, or 
donepezil) along with ICD-10 codes (F00, F01, F02, F03, G30, 
or G31) for medical expense claims submitted to the NHIS. 
AD was diagnosed with the F00 and G30 codes and VaD with 
the F01 code. Other dementias were defined based on the F02, 
F03, and G31 codes, and when dementia subtyping was am-
biguous. Two or more dementia diagnosis codes were some-
times registered together. If primary and secondary diagnoses 
for dementia existed, the dementia subtype was determined 
based on the primary diagnosis. If all dementia codes were 
registered as only secondary diagnoses, the decision was de-
layed until the next visit. If the dementia codes were clarified as 
primary and secondary diagnoses at the next visit, the demen-
tia subtype was defined from the primary diagnosis code. If 
dementia codes were continuously registered as only second-
ary diagnoses, the case was defined as “other dementia.”
Statistical analysis
Data are expressed as mean±standard deviation, geometric 
mean (95% confidence interval [CI]) or percentage. Differenc-
es between groups were identified using the Student’s t-test; the 
chi-square test was used to assess differences in the distribu-
tion of categorical variables. The incidence rates were present-
ed as the number of dementia occurrences per 1,000 person-
years. Multiple Cox proportional hazards regression analysis 
was used to evaluate the association between risk factors and 
development of all types of dementia, AD, or VaD. A compet-
ing risk analysis was completed to determine whether account-
ing for deaths is a competing risk. In addition, the effect of risk 
factors on outcome based on age <60 years versus ≥60 years 
was evaluated. Because the usual age cutoff for YOD and LOD 
is the development of dementia at 65 years of age, the YOD 
and LOD were defined with a baseline age of 60 years, since 
average follow-up time was approximately 5 years in this study. 
To show the association between generalized or central obesity 
and incident dementia, multivariate adjusted incidence rates 
and hazard ratios (HRs) for dementia based on BMI and waist 
circumference (WC) categories were analyzed. All statistical 
results were analyzed using SAS version 9.4 (SAS Institute Inc., 
Cary, NC, USA) and a P<0.05 was considered statistically sig-
nificant. 
RESULTS
Development of dementia (all types, AD, VaD)
During an average of 5.1 years of follow-up, 92,758 partici-
pants developed dementia; 66,092 developed AD, 12,813 de-
veloped VaD, and 13,853 developed other dementia. The inci-
dence rates of all types of dementia, AD, and VaD were 9.5, 6.8, 
and 1.3/1,000 person-years, respectively, in participants with 
diabetes. Although the incidence of dementia sharply in-
creased with age, YOD comprised 4.8% of the total dementia 
occurrence. The incidence rate of YOD was 0.9/1,000 person-
years, in contrast to LOD, which was 17.9/1,000 person-years. 
AD and VaD comprised 55.7% and 26.7% of YOD and 72.0% 
and 13.2% of LOD, respectively. The incidence rates of total 
dementia, AD, and VaD per 1,000 person-years based on age 
groups are shown in Fig. 1. 
Baseline characteristics based on the development of 
dementia
Table 1 shows the baseline characteristics of participants 
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grouped based on future development of dementia. Partici-
pants who were older, female, non-smokers, consumed less al-
cohol or were non-drinkers, and did not exercise had more in-
cident dementia. In addition, subjects who had lower income, 
plasma glucose levels, BMI and WC, and those with hyperten-
sion, dyslipidemia, diabetic vascular complications, and de-
pression developed dementia more frequently. Patients who 
developed dementia had a longer duration of diabetes and 
were treated with OHAs and insulin more frequently than sub-
jects who did not develop dementia. 
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Age- and sex-adjusted risk factor analysis
The effects of variables on the development of dementia after 
adjusting for age and sex were examined (Supplementary Table 
1) and similar to the results shown in Table 1, except for the ef-
fects of smoking; current smoking was a risk factor for demen-
tia in this model. When dementia was specified as AD or VaD, 
the effects of old age and female sex were stronger for incident 
AD than VaD; however, current smoking, hypertension, 
stroke, and CVD had higher HRs for VaD than AD. The other 
variables had similar effects on both AD and VaD (Supple-
mentary Table 1).
Multivariate analysis
Compared with the age- and sex-adjusted model, multiple Cox 
proportional hazard analysis after adjusting for all variables to-
gether did not significantly modify the associations between 
risk factors and dementia, except for mild alcohol intake, 
which became a protective factor, and for dyslipidemia, which 
had a null effect (Table 2). When comparing AD with VaD, fe-
male sex was a risk factor only for AD. Current smoking, hy-
pertension, and stroke showed higher HRs for VaD than AD. 
Fasting plasma glucose (FPG) levels ≥126 mg/dL were a pro-
tective factor for AD but were not significant for VaD. BMI had 
a divergent effect on dementia; low BMI (≤18.5 kg/m2) was a 






Age, yr 59.1±10.3 72.2±7.3 <0.001
Male sex 1,074,414 (58.9) 35,923 (38.7) <0.001
BMI, kg/m2 25.1±3.3 24.3±3.3 <0.001
WC, cm 85.6±8.4 85.1±8.7 <0.001
Current smoker 428,508 (23.5) 11,135 (12.0) <0.001
Heavy drinker 149,352 (8.2) 3,201 (3.5) <0.001
Regular exercise 881,117 (48.3) 28,625 (30.9) <0.001
Income (lower 20%) 398,762 (21.9) 20,681 (22.3) 0.001
FPG ≥126 mg/dL 124,266 (68.1) 51,398 (55.4) <0.001
Duration of diabetes ≥5 yr 649,073 (35.6) 48,059 (51.8) <0.001
Hypertension 1,115,305 (61.1) 70,535 (76.0) <0.001
Dyslipidemia 818,380 (44.8) 42,800 (46.1) <0.001
Diabetic retinopathy 181,489 (9.9) 13,960 (15.1) <0.001
CKD 213,615 (11.7) 25,680 (27.7) <0.001
Stroke 42,827 (2.4) 6,338 (6.8) <0.001
IHD 107,463 (5.9) 10,028 (10.8) <0.001
CVD 142,589 (7.8) 15,422 (16.6) <0.001
Depression 108,996 (6.0) 14,918 (16.1) <0.001
No. of OHAs <0.001
   0 603,706 (33.1) 18,096 (19.5)
   1 388,212 (21.3) 22,761 (24.5)
   ≥2 833,026 (45.7) 51,901 (56.0)
Insulin treatment 163,683 (9.0) 15,462 (16.7) <0.001
Values are presented as mean±standard deviation or number (%). 
BMI, body mass index; WC, waist circumference; FPG, fasting plasma glucose; CKD, chronic kidney disease; IHD, ischemic heart disease; 
CVD, cardiovascular disease; OHA, oral hypoglycemic agent. 
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risk factor but high BMI (≥23 kg/m2) was a protective factor 
for both AD and VaD, with stronger effects on AD than VaD. 
However, in a competing risk analysis where death was consid-
ered a competing risk, female sex was also a risk factor for VaD 
as well as AD. Low BMI was not a risk factor for VaD but very 
high BMI (≥30 kg/m2) was a protective factor for VaD. 
Risk factors for YOD and LOD
When the same analysis was repeated to examine the moderat-
ing effect of age (Table 3), most risk factors had a greater influ-
ence on YOD than on LOD, especially low BMI, history of 
stroke, and depression. However, female sex was a stronger risk 
factor for the development of AD in LOD than in YOD. FPG 




Age 1.13 (1.13–1.14) 1.14 (1.14–1.14) 1.11 (1.10–1.11)
Female sex 1.20 (1.18–1.22) 1.26 (1.23–1.28) 1.01 (0.96–1.06)
Smoker
   Ex 0.91 (0.89–0.93) 0.92 (0.89–0.94) 0.90 (0.85–0.96)
   Current 1.15 (1.13–1.18) 1.12 (1.09–1.15) 1.34 (1.26–1.42)
Drinker
   Mild 0.83 (0.82–0.85) 0.82 (0.80–0.84) 0.86 (0.82–0.91)
   Heavy 1.01 (0.97–1.04) 0.99 (0.94–1.03) 0.95 (0.86–1.04)
Exercise 0.80 (0.79–0.82) 0.82 (0.80–0.83) 0.75 (0.73–0.78)
Income (lower 20%) 1.10 (1.08–1.11) 1.09 (1.07–1.11) 1.09 (1.04–1.13)
FPG ≥126 mg/dL 0.98 (0.97–1.00) 0.97 (0.95–0.99) 1.03 (0.99–1.07)
DM duration ≥5 yr 1.13 (1.11–1.15) 1.13 (1.11–1.15) 1.11 (1.06–1.15)
BMI, kg/m2
   <18.5 1.26 (1.21–1.31) 1.26 (1.21–1.32) 1.13 (1.01–1.27)
   18.5–23 1 (reference) 1 (reference) 1 (reference)
   23–25 0.84 (0.83–0.86) 0.84 (0.83–0.86) 0.87 (0.83–0.91)
   25–30 0.78 (0.77–0.80) 0.77 (0.76–0.79) 0.84 (0.81–0.88)
   >30 0.75 (0.72–0.77) 0.74 (0.71–0.77) 0.80 (0.74–0.87)
Hypertension 1.06 (1.04–1.08) 1.03 (1.01–1.05) 1.26 (1.20–1.31)
Dyslipidemia 0.99 (0.98–1.00) 0.99 (0.98–1.01) 0.97 (0.94–1.01)
Diabetic retinopathy 1.09 (1.07–1.11) 1.10 (1.07–1.12) 1.08 (1.03–1.14)
CKD 1.16 (1.15–1.18) 1.15 (1.13–1.17) 1.18 (1.13–1.23)
Stroke 1.84 (1.79–1.88) 1.57 (1.52–1.62) 3.34 (3.16–3.53)
IHD 1.06 (1.04–1.08) 1.07 (1.05–1.10) 1.07 (1.01–1.13)
Depression 1.93 (1.89–1.96) 1.94 (1.90–1.98) 1.77 (1.68–1.86)
No. of OHAs
   1 1.16 (1.14–1.18) 1.15 (1.12–1.18) 1.20 (1.14–1.27)
   ≥2 1.04 (1.02–1.06) 1.03 (1.01–1.06) 1.09 (1.03–1.16)
Insulin treatment 1.52 (1.50–1.55) 1.49 (1.45–1.52) 1.62 (1.54–1.70)
Values are presented as hazard ratio (95% confidence interval). Analyses adjusted for age, sex, smoking, alcohol intake, exercise, income, plasma 
glucose concentration, duration of diabetes, BMI, dyslipidemia, hypertension, diabetic retinopathy, CKD, stroke, IHD, depression, number of 
OHAs, and treatment with insulin. 
AD, Alzheimer’s disease; VaD, vascular dementia; ANY, all-cause dementia; FPG, fasting plasma glucose; DM, diabetes mellitus; BMI, body 
mass index; CKD, chronic kidney disease; IHD, ischemic heart disease; OHA, oral hypoglycemic agent. 
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levels ≥126 mg/dL were a protective factor for AD in YOD but 
a risk factor for VaD in LOD. 
The effects of BMI or WC on dementia based on age were 
compared (Fig. 2). After adjusting for several confounding fac-
tors, consistent negative associations were observed between 
BMI and dementia in YOD and LOD patients, with a higher 
impact of underweight on YOD compared with LOD (P for 
interaction <0.001) (Fig. 2A). A slight U-shaped association 
was observed between WC and dementia; lower WC (males 
≤85 cm, females ≤80 cm) was associated with a higher risk of 
dementia. Although the effect was weaker, higher WC (males 
>100 cm, females >95 cm) also increased the risk of dementia 
regardless of age (Fig. 2B). 
DISCUSSION
In the present study, the incidence and risk factors for demen-
tia were observed in participants with diabetes using Korean 
Table 3. Multivariate Cox proportional analysis for development of any type of dementia, Alzheimer’s disease, or vascular demen-
tia based on 60 years of age
Characteristic
<60 years ≥60 years
ANY AD VaD ANY AD VaD
Age 1.17 (1.17–1.18) 1.20 (1.20–1.21) 1.12 (1.11–1.13) 1.11 (1.11–1.11) 1.11 (1.11–1.12) 1.08 (1.08–1.09)
Female sex 1.06 (1.01–1.12) 1.13 (1.06–1.20) 0.92 (0.83–1.03) 1.23 (1.21–1.26) 1.29 (1.26–1.32) 1.04 (0.99–1.09)
Smoker
   Ex 0.85 (0.80–0.90) 0.84 (0.78–0.90) 0.87 (0.76–0.99) 0.93 (0.91–0.96) 0.94 (0.91–0.96) 0.92 (0.86–0.98)
   Current 1.24 (1.17–1.31) 1.17 (1.09–1.25) 1.43 (1.28–1.60) 1.14 (1.11–1.17) 1.12 (1.09–1.16) 1.30 (1.22–1.39)
Drinker
   Mild 0.83 (0.80–0.87) 0.83 (0.78–0.88) 0.84 (0.76–0.93) 0.85 (0.83–0.87) 0.84 (0.81–0.86) 0.89 (0.83–0.94)
   Heavy 1.00 (0.93–1.08) 0.98 (0.89–1.08) 0.93 (0.80–1.09) 1.04 (1.00–1.09) 1.03 (0.98–1.09) 0.97 (0.86–1.09)
Exercise 0.75 (0.73–0.78) 0.75 (0.72–0.79) 0.71 (0.66–0.77) 0.81 (0.79–0.82) 0.82 (0.81–0.84) 0.76 (0.73–0.80)
Low incomea 1.26 (1.21–1.30) 1.28 (1.22–1.34) 1.24 (1.14–1.35) 1.07 (1.05–1.09) 1.07 (1.05–1.09) 1.04 (0.99–1.09)
FPG ≥126 mg/dL 0.95 (0.91–0.99) 0.93 (0.89–0.97) 0.99 (0.91–1.08) 1.01 (0.99–1.02) 0.99 (0.97–1.01) 1.05 (1.01–1.10)
DM duration ≥5 yr 1.18 (1.14–1.23) 1.18 (1.12–1.24) 1.18 (1.08–1.29) 1.10 (1.08–1.12) 1.10 (1.08–1.12) 1.07 (1.02–1.12)
BMI <18.5 kg/m2 1.85 (1.64–2.07) 1.94 (1.68–2.24) 1.56 (1.18–2.06) 1.26 (1.21–1.31) 1.26 (1.20–1.33) 1.10 (0.97–1.25)
Hypertension 1.19 (1.14–1.24) 1.10 (1.05–1.16) 1.50 (1.38–1.64) 1.01 (1.00–1.03) 0.99 (0.97–1.01) 1.16 (1.10–1.21)
Dyslipidemia 0.97 (0.93–1.00) 0.98 (0.93–1.02) 1.00 (0.92–1.08) 0.99 (0.97–1.00) 0.99 (0.97–1.00) 0.96 (0.92–1.00)
Diabetic retinopathy 1.13 (1.08–1.19) 1.14 (1.07–1.21) 1.19 (1.06–1.32) 1.06 (1.03–1.08) 1.06 (1.04–1.09) 1.03 (0.97–1.09)
CKD 1.25 (1.19–1.31) 1.23 (1.15–1.30) 1.25 (1.12–1.40) 1.17 (1.15–1.19) 1.16 (1.14–1.18) 1.18 (1.13–1.23)
Stroke 3.15 (2.96–3.36) 2.62 (2.40–2.86) 4.88 (4.32–5.51) 1.67 (1.62–1.71) 1.44 (1.39–1.49) 3.03 (2.85–3.22)
IHD 1.16 (1.09–1.24) 1.17 (1.08–1.27) 1.27 (1.11–1.46) 1.04 (1.01–1.06) 1.05 (1.02–1.07) 1.02 (0.96–1.09)
Depression 2.62 (2.50–2.75) 2.74 (2.59–2.91) 2.09 (1.87–2.34) 1.81 (1.78–1.85) 1.83 (1.79–1.87) 1.68 (1.59–1.78)
No. of OHAs
   1 1.08 (1.03–1.14) 1.10 (1.03–1.17) 1.08 (0.97–1.21) 1.14 (1.11–1.16) 1.11 (1.09–1.14) 1.21 (1.14–1.28)
   ≥2 0.99 (0.94–1.05) 1.01 (0.94–1.09) 0.95 (0.84–1.07) 1.02 (0.99–1.04) 1.00 (0.98–1.03) 1.10 (1.03–1.18)
Insulin treatment 1.78 (1.69–1.86) 1.78 (1.67–1.88) 1.72 (1.55–1.90) 1.46 (1.43–1.49) 1.43 (1.39–1.46) 1.57 (1.49–1.65)
Values are presented as hazard ratios (95% confidence interval). Analyses adjusted for age, sex, smoking, alcohol intake, exercise, income, plas-
ma glucose concentration, duration of diabetes, BMI, dyslipidemia, hypertension, diabetic retinopathy, CKD, stroke, IHD, depression, number 
of OHAs, and treatment with insulin.
AD, Alzheimer’s disease; VaD, vascular dementia; ANY, all-cause dementia; FPG, fasting plasma glucose; DM, diabetes mellitus; BMI, body 
mass index; CKD, chronic kidney disease; IHD, ischemic heart disease; OHA, oral hypoglycemic agent.
aIncome level was dichotomized at the lower 20%. 
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representative data. The overall incidence of dementia in dia-
betes was 9.5/1,000 person-years and increased exponentially 
with age. Participants at higher risk of dementia were females, 
smokers, had low income, long duration of diabetes, were tak-
ing more hypoglycemic agents, and had micro- and macrovas-
cular complications, hypertension, depression, or were under-
weight. Mild alcohol intake, regular exercise, and being over-
weight were protective factors for dementia in people with dia-
betes. The incidence rate of YOD was 0.9/1,000 person-years, 
and risk factors were similar to LOD; however, the HRs of low 
BMI, low WC, a history of stroke, and depression were signifi-
cantly higher for YOD than LOD. 
The difference between the incidence and risk factors for AD 
and VaD in subjects with diabetes was compared in this study. 
In developed countries, the ratio of AD/VaD is higher than in 
developing countries [18]. According to a meta-analysis of epi-
Fig. 2. Hazard ratios (HRs) for all-cause dementia, Alzheimer’s disease (AD), and vascular dementia (VaD) based on (A) body 
mass index (BMI) or (B) waist circumference. Analyses were adjusted for age, sex, smoking, alcohol intake, exercise, income, 
plasma glucose concentration, duration of diabetes, dyslipidemia, hypertension, diabetic retinopathy, chronic kidney disease, 
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demiologic studies on dementia in Korea, the AD/VaD ratio 
increased from 1.96 in the early 1990s to 4.13 in the 2010s [19]. 
In the present study, the ratio was approximately 5.2 in people 
with diabetes, and vascular risk factors such as smoking, hy-
pertension, and stroke showed higher HRs for VaD than AD. 
Because diabetes is a well-known risk factor for VaD [20], the 
improvement of vascular risk factor management in diabetes 
may be responsible for this relatively lower incidence of VaD 
compared with AD. In this study, the ratio of AD/VaD was 2.1 
for YOD compared with 5.5 for LOD, indicating the incidence 
of VaD in YOD is higher than in LOD. 
In several studies, uncontrolled diabetes was shown associ-
ated with dementia in diabetic subjects [7,21,22]. Similar to re-
sults reported in many previous publications [5,6], duration of 
diabetes and insulin treatment were risk factors for dementia 
in the present study; however, we found high glucose did not 
lead to dementia. The association of high glucose with demen-
tia remains controversial. Bruce et al. [5] showed that glycosyl-
ated hemoglobin and fasting glucose were not associated with 
an increased risk of dementia, whereas Xu et al. [7] found that 
uncontrolled diabetes was associated with an increased risk of 
dementia. Poor glycemic control was associated with greater 
cognitive decline at 70 to 79 years of age [23], but with less de-
cline over 80 years of age in participants with diabetes [24]. Al-
though severe hypoglycemia is a risk factor for dementia [8], 
whether the lower fasting glucose levels of participants in this 
study indicate that more hypoglycemic events were associated 
with more frequent prescription of OHAs or insulin is unclear.
In the present study, being underweight was shown a risk 
factor for dementia. Higher BMI was a protective factor for 
AD and VaD in both age groups. Controversy exists surround-
ing the association between obesity and dementia. In a meta-
analysis, the harmful effects of higher BMI was evident in 
long-term follow-up, although a protective effect was evident 
in short-term follow-up [25], indicating that even if obesity is 
associated with a high risk of dementia, weight loss during the 
preclinical period appears a protective factor (a reverse causal-
ity). This concept was also confirmed in the Whitehall II study, 
in which the BMI trajectory was shown in incident dementia 
for 28 years [26]. The authors explain the inconsistency be-
tween studies was due to insufficient follow-up time, which did 
not take preclinical weight loss into account. Therefore, the 
5.1-year follow-up period in the present study is insufficient 
for accurate differentiation between a real effect of obesity and 
weight loss before the onset of disease. In addition, using BMI 
does not distinguish between changes that are due to altera-
tions in lean mass from adipose mass. Body weight tends to 
decrease as part of normal aging, which might result from a 
combination of muscle and adipose mass loss in late life 
[27,28]. This age-associated change in body composition and 
related hormonal change may promote AD and vascular pa-
thology. Although the mechanism related to the development 
of YOD has yet to be determined, underweight condition due 
to sarcopenia in midlife might explain the strong association 
between YOD and low BMI in the present study. 
In several reports the increasing problem of YOD has been 
demonstrated [10,29,30]; however, the incidence and risk fac-
tors have been evaluated in only a few studies. The YOD inci-
dence rate in the present study was 0.9/1,000 person-years, and 
traditional cardiovascular risk factors such as smoking, hyper-
tension, CKD, stroke, and IHD were associated more strongly 
with YOD than LOD in patients with diabetes. In addition, a 
strong association between YOD and vascular disease includ-
ing stroke, transient ischemic attack, CKD, or hypertension 
was shown in previous studies [31-33]. These results indicate 
that many cases of YOD in individuals with diabetes are pre-
ventable by adequate management of vascular causes. 
A history of depression or stroke had a stronger influence on 
the development of YOD than LOD in people with diabetes. 
The frequency of depression was also higher in subjects with 
YOD than with LOD in the Registry of Dementia of Girona 
[30]. In several longitudinal studies, depression was a major 
risk factor for incidence of dementia [34]. Depression was 
shown to injure neurons by several different mechanisms such 
as inflammation [35], elevated glucocorticoid production [36], 
amyloid deposition [37], or dysfunctional immune activity 
[38], which may lead to cognitive impairment. However, in a 
recent study, depression was a significant risk factor for YOD 
only if occuring within 10 years from YOD onset [32], indicat-
ing that depression might be a prodromal consequence of 
YOD rather than an etiological risk factor. Further research is 
needed to reach a definite conclusion whether the two condi-
tions are linked as risk factors or are part of a continuum. The 
mechanism by which stroke confers an increased risk of YOD 
remains unclear. Stroke may trigger a neurodegenerative pro-
cess by disrupting amyloid clearance [39] or by activating au-
toimmune responses [40] in the brain. Ongoing exposure to 
existing vascular risk factors, immune processes, and patho-
genic mechanisms may contribute to risk of dementia after 
stroke in younger people. 
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The present study had several limitations. First, since the 
Korean insurance claim data was used based on diagnosis 
codes, instances of misdiagnosis or misclassification of diabe-
tes and dementia including its subtypes may have occurred. 
Second, except for the duration of diabetes and controversial 
glycemic control, modifiable factors specific to the patients 
with diabetes compared with known dementia risk factors in 
the general population were not found. Comparison with peo-
ple without diabetes may clarify diabetes-specific risk factors 
for dementia. Nonetheless, to date, this is the largest study in 
which the incidence and risk factors for dementia and its sub-
types were evaluated using a nationally representative cohort 
study of diabetes. 
In conclusion, the incidence and risk factors associated with 
dementia in Korean participants with diabetes were presented 
in this study. Because diabetes is closely associated with de-
mentia and many vascular risk factors for dementia are modi-
fiable, the results may aid in creating effective preventive strat-
egies to decrease the rising dementia epidemic and its related 
health and socioeconomic burden. 
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